Rabbit Recombinant Monoclonal EEF1A2 antibody. Carrier free. Suitable for IP, WB and reacts with Human, Mouse, Rat samples.
pH: 7.2 - 7.4
Constituents: PBS
IP | Flow Cyt | WB | IHC-P | ICC/IF | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Tested | Not recommended | Not recommended |
Mouse | Expected | Not recommended | Tested | Not recommended | Not recommended |
Rat | Expected | Not recommended | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Select an associated product type
This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.
EEF1AL, STN, EEF1A2, Elongation factor 1-alpha 2, EF-1-alpha-2, Eukaryotic elongation factor 1 A-2, Statin-S1, eEF1A-2
Rabbit Recombinant Monoclonal EEF1A2 antibody. Carrier free. Suitable for IP, WB and reacts with Human, Mouse, Rat samples.
pH: 7.2 - 7.4
Constituents: PBS
ab256523 is the carrier-free version of Anti-EEF1A2 antibody [EPR22651-46] ab227824.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
EF1A2 also known as Eukaryotic translation elongation factor 1 alpha 2 is a protein that plays a role in the elongation phase of protein synthesis. It is a GTP-binding protein with a mass of about 50 kDa. This protein facilitates the binding of aminoacyl-tRNA to the acceptor site of the ribosome during protein translation. EF1A2 is expressed mainly in heart brain and skeletal muscle tissues indicating its importance in tissues with high energy demands.
EF1A2 supports cellular proliferation and growth by ensuring the continuous efficiency of protein synthesis. It participates in several protein complexes that are involved in translational control. By regulating the actin cytoskeleton EF1A2 additionally influences cell shape and motility. This multifunctionality indicates EF1A2's relevance in various cellular activities beyond its primary role in translation elongation.
EF1A2 integrates into the protein synthesis pathway and also plays a role in the mTOR signaling pathway which regulates cell growth and metabolism. In the mTOR pathway EF1A2 works alongside other elongation factors like EF2 and components of the translation machinery to coordinate protein synthesis. It interacts with proteins involved in nutrient signaling and energy status showing its role in integrating metabolic signals with translational processes.
EF1A2 shows a connection with cancer and neurodegenerative diseases. Overexpression of EF1A2 has been linked to several types of cancer as its role in facilitating protein synthesis can contribute to uncontrolled cellular proliferation. In neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) altered expression of EF1A2 suggests a disruption in protein homeostasis. The dysregulation of EF1A2 potentially affecting actin-binding proteins like TDP-43 highlights its association with disease pathology.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Anti-EEF1A2 antibody [EPR22651-46] ab227824 was shown to specifically react with EEF1A2 in wild-type HAP1 cells as signal was lost in EEF1A2 knockout cells. Wild-type and EEF1A2 knockout samples were subjected to SDS-PAGE. Anti-EEF1A2 antibody [EPR22651-46] ab227824 and Anti-GAPDH antibody [EPR16891] - Loading Control ab181602 (Rabbit anti-GAPDH loading control) were incubated 1 hour at room temperature at 1/1000 dilution and 1/200,000 dilution respectively. Blots were developed with Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051) secondary antibody at 1/100,000 dilution for 1 hour at room temperature before imaging. The blot was developed on a BIO-RAD® ChemiDoc™ MP instrument using the ECL technique.
This antibody also recognizes a weakly unidentifiable band at around 75kDa
Blocking/diluting buffer and concentration: 5% NFDM/TBST
Exposure time: 3.25 seconds
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-EEF1A2 antibody [EPR22651-46] ab227824).
All lanes: Western blot - Anti-EEF1A2 antibody [EPR22651-46] (Anti-EEF1A2 antibody [EPR22651-46] ab227824) at 1/1000 dilution
Lane 1: Wild-type HAP1 whole cell lysate at 20 µg
Lane 2: EEF1A2 knockout HAP1 whole cell lysate at 20 µg
Lane 3: HEK-293T (human embryonic kidney epithelial cell), whole cell lysate at 20 µg
Lane 4: Neuro-2a (mouse neuroblastoma neuroblast), whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 50 kDa
Observed band size: 50 kDa
EEF1A2 was immunoprecipitated from 0.35 mg HEK-293T (human embryonic kidney epithelial cell) whole cell lysate with Anti-EEF1A2 antibody [EPR22651-46] ab227824 at 1/30 dilution (2μg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using Anti-EEF1A2 antibody [EPR22651-46] ab227824 1/1000 dilution (0.54 μg/ml). VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) was used as the secondary antibody at 1/5000 dilution.
Lane 1: HEK-293T (human embryonic kidney epithelial cell) whole cell lysate 10μg
Lane 2: Anti-EEF1A2 antibody [EPR22651-46] ab227824 IP in HEK-293T whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-EEF1A2 antibody [EPR22651-46] ab227824 in HEK-293T whole cell lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 15 seconds
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-EEF1A2 antibody [EPR22651-46] ab227824).
All lanes: Immunoprecipitation - Anti-EEF1A2 antibody [EPR22651-46] (Anti-EEF1A2 antibody [EPR22651-46] ab227824)
Predicted band size: 47 kDa, 50 kDa
Observed band size: 46 kDa, 50 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com